Myeloma UK New Drug Scanner

Summary:
Thalidomide belongs to a class of drugs called immunomodulatory drugs (IMiDs).

Thalidomide belongs to a class of drugs called immunomodulatory drugs (IMiDs).

Summary:
Velcade is the first in a new class of anti-cancer drugs called proteasome inhibitors.

Velcade is the first in a new class of anti-cancer drugs called proteasome inhibitors.

Summary:
Revlimid is a derivative of thalidomide and belongs to a class of drugs called immunomodulatory drugs (IMiDs).

Revlimid is a derivative of thalidomide and belongs to a class of drugs called immunomodulatory drugs (IMiDs).

Summary:
Mozobil is an immunostimulant used to help mobilise stem cells from the bone marrow.

Mozobil is an immunostimulant used to help mobilise stem cells from the bone marrow.

Summary:
Bendamustine is a chemotherapy agent that belongs to a class of drugs called alkylating agents.

Bendamustine is a chemotherapy agent that belongs to a class of drugs called alkylating agents.

Summary:
Denosumab is a fully human monoclonal antibody which targets the RANKL molecule thereby preventing bone breakdown.

Denosumab is a fully human monoclonal antibody which targets the RANKL molecule thereby preventing bone breakdown.

Summary:
Panobinostat belongs to a new class of drugs called histone deacetylase inhibitors which are being tested for the treatment of myeloma and other cancers.

Panobinostat belongs to a new class of drugs called histone deacetylase inhibitors which are being tested for the treatment of myeloma and other cancers.

Panobinostat LBH 589 is a showcase drug This drug is currently a showcase drug

Summary:
Perifosine is a novel type of anti-cancer drug which works by blocking signalling pathways that control cell survival, causing cells to die.

Perifosine is a novel type of anti-cancer drug which works by blocking signalling pathways that control cell survival, causing cells to die.

Perifosine KRX 0401 is a showcase drug This drug is currently a showcase drug

Summary:
Oblimersen is an antisense oligonucleotide against the protein bcl 2, which is required by cells for survival. Bcl 2 is much more highly expressed in myeloma and other cancer cells. Oblimerson works by stopping myeloma cells from making bcl 2, causing them to die.

Oblimersen is an antisense oligonucleotide against the protein bcl 2, which is required by cells for survival. Bcl 2 is much more highly expressed in myeloma and other cancer cells. Oblimerson works by stopping myeloma cells from making bcl 2, causing them to die.

Summary:
Plitidepsin is an antitumour agent of marine origin. It inhibits multiple signalling pathways required for cell growth and survival, causing myeloma cells to undergo cell suicide.

Plitidepsin is an antitumour agent of marine origin. It inhibits multiple signalling pathways required for cell growth and survival, causing myeloma cells to undergo cell suicide.

Summary:
Vorinostat belongs to a new class of drugs called histone deacetylase inhibitors which are being tested for the treatment of myeloma and other cancers.

Vorinostat belongs to a new class of drugs called histone deacetylase inhibitors which are being tested for the treatment of myeloma and other cancers.

Summary:
Carfilzomib is a second generation proteasome inhibitor which works in a similar way to Velcade by blocking the breakdown of proteins, causing cells to undergo cell suicide. Carfilzomib is more selective than Velcade and does not appear to cause peripheral neuropathy.

Carfilzomib is a second generation proteasome inhibitor which works in a similar way to Velcade by blocking the breakdown of proteins, causing cells to undergo cell suicide. Carfilzomib is more selective than Velcade and does not appear to cause peripheral neuropathy.

Carfilzomib PR-171 is a showcase drug This drug is currently a showcase drug

Summary:
Elotuzumab is a humanised monoclonal antibody which targets myeloma cells by binding to the CS1 molecule, causing the immune system to attack and kill the myeloma cells.

Elotuzumab is a humanised monoclonal antibody which targets myeloma cells by binding to the CS1 molecule, causing the immune system to attack and kill the myeloma cells.

Elotuzumab HuLuc 63 is a showcase drug This drug is currently a showcase drug

Summary:
Pomalidomide is a derivative of thalidomide and belongs to a class of drugs called immunomodulatory drugs (IMiDs).

Pomalidomide is a derivative of thalidomide and belongs to a class of drugs called immunomodulatory drugs (IMiDs).

Pomalidomide CC-4047 is a showcase drug This drug is currently a showcase drug

Summary:
ACE 011 is an activin receptor IIA inhibitor which promotes new bone formation and increases bone mineral density.

ACE 011 is an activin receptor IIA inhibitor which promotes new bone formation and increases bone mineral density.

Summary:
Azacitidine is a chemotherapy agent which works by incorporating itself into DNA and blocking the actions of a protein called DNA methyltransferase. This results in increased levels of proteins being made that stop myeloma and other cancer cells from growing.

Azacitidine is a chemotherapy agent which works by incorporating itself into DNA and blocking the actions of a protein called DNA methyltransferase. This results in increased levels of proteins being made that stop myeloma and other cancer cells from growing.

Summary:
Bevacizumab is a humanised monoclonal antibody which targets vascular endothelial growth factor-A (VEGF-A) and prevents the formation of new blood vessels.

Bevacizumab is a humanised monoclonal antibody which targets vascular endothelial growth factor-A (VEGF-A) and prevents the formation of new blood vessels.

Summary:
Cetuximab is a monoclonal antibody which targets epidermal growth factor receptor (EGFR) and prevents cell growth and survival, causing cells to die.

Cetuximab is a monoclonal antibody which targets epidermal growth factor receptor (EGFR) and prevents cell growth and survival, causing cells to die.

Summary:
TKI 258 is an oral tyrosine kinase inhibitor which blocks cell growth, metabolism and survival.

TKI 258 is an oral tyrosine kinase inhibitor which blocks cell growth, metabolism and survival.

Summary:
Darinoparsin is a novel organic arsenic which is toxic to myeloma and other cancer cells.

Darinoparsin is a novel organic arsenic which is toxic to myeloma and other cancer cells.